Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.35
AZN's Cash to Debt is ranked higher than
54% of the 1176 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.65 vs. AZN: 0.35 )
AZN' s 10-Year Cash to Debt Range
Min: 0.2   Max: N/A
Current: 0.35

Equity to Asset 0.32
AZN's Equity to Asset is ranked higher than
51% of the 978 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.59 vs. AZN: 0.32 )
AZN' s 10-Year Equity to Asset Range
Min: 0.3   Max: 0.59
Current: 0.32

0.3
0.59
Interest Coverage 5.58
AZN's Interest Coverage is ranked higher than
50% of the 625 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 160.63 vs. AZN: 5.58 )
AZN' s 10-Year Interest Coverage Range
Min: 5.58   Max: 100.5
Current: 5.58

5.58
100.5
F-Score: 3
Z-Score: 2.13
M-Score: -2.92
WACC vs ROIC
8.14%
8.07%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) 8.60
AZN's Operating margin (%) is ranked higher than
72% of the 1120 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9.84 vs. AZN: 8.60 )
AZN' s 10-Year Operating margin (%) Range
Min: 8.19   Max: 38.09
Current: 8.6

8.19
38.09
Net-margin (%) 4.89
AZN's Net-margin (%) is ranked higher than
69% of the 1120 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.55 vs. AZN: 4.89 )
AZN' s 10-Year Net-margin (%) Range
Min: 4.73   Max: 29.72
Current: 4.89

4.73
29.72
ROE (%) 6.33
AZN's ROE (%) is ranked higher than
72% of the 1163 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.30 vs. AZN: 6.33 )
AZN' s 10-Year ROE (%) Range
Min: 5.9   Max: 45.52
Current: 6.33

5.9
45.52
ROA (%) 2.21
AZN's ROA (%) is ranked higher than
68% of the 1187 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.54 vs. AZN: 2.21 )
AZN' s 10-Year ROA (%) Range
Min: 2.2   Max: 20.87
Current: 2.21

2.2
20.87
ROC (Joel Greenblatt) (%) 36.89
AZN's ROC (Joel Greenblatt) (%) is ranked higher than
87% of the 1182 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 15.91 vs. AZN: 36.89 )
AZN' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 36.93   Max: 191.23
Current: 36.89

36.93
191.23
Revenue Growth (3Y)(%) -5.70
AZN's Revenue Growth (3Y)(%) is ranked higher than
57% of the 974 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.70 vs. AZN: -5.70 )
AZN' s 10-Year Revenue Growth (3Y)(%) Range
Min: -42.9   Max: 20
Current: -5.7

-42.9
20
EBITDA Growth (3Y)(%) -30.70
AZN's EBITDA Growth (3Y)(%) is ranked higher than
54% of the 882 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.40 vs. AZN: -30.70 )
AZN' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -38.9   Max: 24.7
Current: -30.7

-38.9
24.7
EPS Growth (3Y)(%) -48.90
AZN's EPS Growth (3Y)(%) is ranked higher than
51% of the 834 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.40 vs. AZN: -48.90 )
AZN' s 10-Year EPS Growth (3Y)(%) Range
Min: -48.9   Max: 24.7
Current: -48.9

-48.9
24.7
» AZN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

AZN Guru Trades in Q2 2014

Jeremy Grantham 28,000 sh (New)
Louis Moore Bacon 40,000 sh (New)
Paul Tudor Jones 27,100 sh (New)
George Soros 150,000 sh (New)
Mario Gabelli 40,400 sh (New)
Jim Simons 1,794,800 sh (+25.60%)
Steven Cohen 370,800 sh (unchged)
Francis Chou 13,000 sh (unchged)
Steven Cohen 225,000 sh (unchged)
Daniel Loeb 1,000,000 sh (unchged)
Joel Greenblatt Sold Out
Murray Stahl 13,000 sh (-0.81%)
John Hussman 223,500 sh (-1.97%)
David Dreman 117,832 sh (-13.00%)
NWQ Managers 64,475 sh (-24.55%)
Manning & Napier Advisors, Inc 309,030 sh (-32.76%)
Stanley Druckenmiller 208,900 sh (-42.05%)
Pioneer Investments 225,804 sh (-50.84%)
Charles Brandes 386,058 sh (-71.06%)
» More
Q3 2014

AZN Guru Trades in Q3 2014

Steven Cohen 611,100 sh (+64.81%)
Mario Gabelli 41,900 sh (+3.71%)
Jim Simons 1,847,100 sh (+2.91%)
Manning & Napier Advisors, Inc 317,180 sh (+2.64%)
George Soros 150,000 sh (unchged)
Steven Cohen 400,000 sh (unchged)
Murray Stahl 13,000 sh (unchged)
Francis Chou 13,000 sh (unchged)
Pioneer Investments 227,221 sh (unchged)
NWQ Managers 64,475 sh (unchged)
Jeremy Grantham Sold Out
Stanley Druckenmiller Sold Out
Charles Brandes Sold Out
Paul Tudor Jones Sold Out
David Dreman 117,003 sh (-0.70%)
John Hussman 173,500 sh (-22.37%)
Louis Moore Bacon 30,000 sh (-25.00%)
» More
Q4 2014

AZN Guru Trades in Q4 2014

Pioneer Investments 754,327 sh (+231.98%)
Jim Simons 2,287,900 sh (+23.86%)
NWQ Managers 66,440 sh (+3.05%)
John Hussman 173,500 sh (unchged)
Francis Chou 13,000 sh (unchged)
Murray Stahl 13,000 sh (unchged)
George Soros Sold Out
Louis Moore Bacon Sold Out
Steven Cohen 587,400 sh (-3.88%)
Manning & Napier Advisors, Inc 227,870 sh (-28.16%)
Mario Gabelli 19,900 sh (-52.51%)
David Dreman 28,764 sh (-75.42%)
» More
Q1 2015

AZN Guru Trades in Q1 2015

Jim Simons 3,154,400 sh (+37.87%)
Pioneer Investments 758,498 sh (+0.55%)
Manning & Napier Advisors, Inc 227,870 sh (unchged)
Francis Chou 13,000 sh (unchged)
Murray Stahl 13,000 sh (unchged)
David Dreman 27,489 sh (-4.43%)
NWQ Managers 52,265 sh (-21.34%)
Mario Gabelli 11,800 sh (-40.70%)
John Hussman 52,000 sh (-70.03%)
Steven Cohen 61,800 sh (-89.48%)
» More
» Details

Insider Trades

Latest Guru Trades with AZN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 71.30
AZN's P/E(ttm) is ranked higher than
71% of the 1294 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 60.50 vs. AZN: 71.30 )
AZN' s 10-Year P/E(ttm) Range
Min: 6.04   Max: 99.46
Current: 71.3

6.04
99.46
Forward P/E 16.61
AZN's Forward P/E is ranked higher than
92% of the 1294 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.00 vs. AZN: 16.61 )
N/A
PE(NRI) 71.80
AZN's PE(NRI) is ranked higher than
73% of the 1294 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 59.20 vs. AZN: 71.80 )
AZN' s 10-Year PE(NRI) Range
Min: 6.02   Max: 99.71
Current: 71.8

6.02
99.71
P/B 4.99
AZN's P/B is ranked higher than
62% of the 1294 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.15 vs. AZN: 4.99 )
AZN' s 10-Year P/B Range
Min: 2.3   Max: 6.97
Current: 4.99

2.3
6.97
P/S 3.50
AZN's P/S is ranked higher than
67% of the 1294 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.31 vs. AZN: 3.50 )
AZN' s 10-Year P/S Range
Min: 1.61   Max: 3.9
Current: 3.5

1.61
3.9
PFCF 35.23
AZN's PFCF is ranked higher than
85% of the 1294 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 662.20 vs. AZN: 35.23 )
AZN' s 10-Year PFCF Range
Min: 6.18   Max: 38.17
Current: 35.23

6.18
38.17
POCF 15.92
AZN's POCF is ranked higher than
89% of the 1294 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 43.64 vs. AZN: 15.92 )
AZN' s 10-Year POCF Range
Min: 5.35   Max: 20.64
Current: 15.92

5.35
20.64
EV-to-EBIT 43.08
AZN's EV-to-EBIT is ranked higher than
75% of the 1294 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 42.19 vs. AZN: 43.08 )
AZN' s 10-Year EV-to-EBIT Range
Min: 4.5   Max: 55.6
Current: 43.08

4.5
55.6
Shiller P/E 16.09
AZN's Shiller P/E is ranked higher than
96% of the 1294 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.00 vs. AZN: 16.09 )
AZN' s 10-Year Shiller P/E Range
Min: 8.02   Max: 25.8
Current: 16.09

8.02
25.8
Current Ratio 0.81
AZN's Current Ratio is ranked lower than
53% of the 1057 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.27 vs. AZN: 0.81 )
AZN' s 10-Year Current Ratio Range
Min: 0.64   Max: 2.03
Current: 0.81

0.64
2.03
Quick Ratio 0.68
AZN's Quick Ratio is ranked higher than
50% of the 1057 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.70 vs. AZN: 0.68 )
AZN' s 10-Year Quick Ratio Range
Min: 0.54   Max: 2.03
Current: 0.68

0.54
2.03
Days Inventory 131.45
AZN's Days Inventory is ranked higher than
72% of the 1294 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 145.57 vs. AZN: 131.45 )
AZN' s 10-Year Days Inventory Range
Min: 88.45   Max: 291.08
Current: 131.45

88.45
291.08
Days Sales Outstanding 105.82
AZN's Days Sales Outstanding is ranked higher than
67% of the 1294 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 91.38 vs. AZN: 105.82 )
AZN' s 10-Year Days Sales Outstanding Range
Min: 52.89   Max: 127.8
Current: 105.82

52.89
127.8

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 4.03
AZN's Dividend Yield is ranked higher than
97% of the 697 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.25 vs. AZN: 4.03 )
AZN' s 10-Year Dividend Yield Range
Min: 1.76   Max: 7.65
Current: 4.03

1.76
7.65
Dividend Payout 2.77
AZN's Dividend Payout is ranked higher than
74% of the 1294 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.00 vs. AZN: 2.77 )
AZN' s 10-Year Dividend Payout Range
Min: 0.23   Max: 4.87
Current: 2.77

0.23
4.87
Dividend growth (3y) -2.00
AZN's Dividend growth (3y) is ranked higher than
68% of the 489 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.80 vs. AZN: -2.00 )
AZN' s 10-Year Dividend growth (3y) Range
Min: -4.5   Max: 28.3
Current: -2

-4.5
28.3
Yield on cost (5-Year) 5.43
AZN's Yield on cost (5-Year) is ranked higher than
97% of the 704 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.50 vs. AZN: 5.43 )
AZN' s 10-Year Yield on cost (5-Year) Range
Min: 2.39   Max: 10.38
Current: 5.43

2.39
10.38
Share Buyback Rate 2.60
AZN's Share Buyback Rate is ranked higher than
96% of the 770 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -1.50 vs. AZN: 2.60 )
AZN' s 10-Year Share Buyback Rate Range
Min: 4.6   Max: -123.9
Current: 2.6

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 1.32
AZN's Price/DCF (Projected) is ranked higher than
93% of the 1294 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.00 vs. AZN: 1.32 )
AZN' s 10-Year Price/DCF (Projected) Range
Min: 0.49   Max: 4.49
Current: 1.32

0.49
4.49
Price/Median PS Value 1.46
AZN's Price/Median PS Value is ranked higher than
70% of the 1294 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.51 vs. AZN: 1.46 )
AZN' s 10-Year Price/Median PS Value Range
Min: 0.69   Max: 2.44
Current: 1.46

0.69
2.44
Earnings Yield (Greenblatt) 2.30
AZN's Earnings Yield (Greenblatt) is ranked higher than
71% of the 1174 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.90 vs. AZN: 2.30 )
AZN' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1.8   Max: 22.3
Current: 2.3

1.8
22.3
Forward Rate of Return (Yacktman) -13.66
AZN's Forward Rate of Return (Yacktman) is ranked higher than
57% of the 603 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.53 vs. AZN: -13.66 )
AZN' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -15.7   Max: 27.7
Current: -13.66

-15.7
27.7

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:GSK, JNJ, PFE, RHHBY, NVS » details
Traded in other countries:AZN.Sweden, AZNDF.USA, AZN.UK, ZEGA.Germany, ZEG.Germany, AZNCF.USA, AZN N.Mexico, AZN.Switzerland,
AstraZeneca PLC was incorporated in England and Wales on June 17, 1992. From February 1993 until April 1999, the Company was called Zeneca Group PLC. On 6 April 1999, the Company changed its name to AstraZeneca PLC. It is a biopharmaceutical company. The Company is engaged in the discovery and development of new products, which are then manufactured, marketed and sold. It is engaged in healthcare: Cardiovascular and Metabolic disease (CVMD); Oncology; and Respiratory, Inflammation and Autoimmunity (RIA). The Company is also engaged in the Infection, Neuroscience and Gastrointestinal (ING) disease areas. It operates in more than 100 countries.
» More Articles for AZN

Headlines

Articles On GuruFocus.com
Johnson & Johnson A Good Investment Despite Current Lows May 14 2015 
Vanguard Adds to Four of Its Largest Stakes May 04 2015 
HealthCare Stocks That Can Make Investors Healthier Apr 08 2015 
Regulus Therapeutics (RGLS) microRNA Therapeutic Milestone Payment, Dave & Buster's Entertainment (P Apr 08 2015 
Pfizer Stocks Has A Lot Of Steam To Take The Investors Higher Jan 20 2015 
Merck Takes A Step Forward In The World Of Medicine Jan 16 2015 
Brandes International Equity Fund Q3 Commentary Dec 23 2014 
Blackhill Bets Almost Half of Portfolio on Williams-Sonoma Nov 10 2014 
A Look at the Top Five Medical Stocks Held in the Vanguard Portfolio Nov 09 2014 
Steven Cohen Has a Track Record of Impressive Returns Jul 31 2014 

More From Other Websites
Amgen Ends Psoriasis-Drug Partnership With AstraZeneca May 22 2015
Amgen ends partnership with AstraZeneca on psoriasis drug May 22 2015
Amgen ends partnership with AstraZeneca on psoriasis drug May 22 2015
Amgen ends work on experimental psoriasis drug May 22 2015
Amgen ends work on experimental psoriasis drug May 22 2015
Amgen ends collaboration with AstraZeneca on inflammation drug May 22 2015
Amgen ends collaboration with AstraZeneca on inflammation drug May 22 2015
AstraZeneca provides update on brodalumab development programme May 22 2015
Amgen to terminate participation in co-development and commercialization of brodalumab May 22 2015
Startup AdverseEvents makes side effects a factor in the cost of a drug May 22 2015
Jefferies Makes Changes to Top Pharmaceutical Stocks to Buy May 22 2015
All Eyes on Pfizer as Shareholders Await the Mega-Deal: Real M&A May 21 2015
Olympic Gold Medalist Jackie Joyner-Kersee Teams up with AstraZeneca to Raise Awareness about... May 20 2015
Houston, Johnson & Johnson May Have a Problem May 19 2015
Shire Has Outperformed AstraZeneca After Acquisition Bids For Both Failed To Materialize May 19 2015
AstraZeneca Reports Data from KODIAC studies on Movantik - Analyst Blog May 18 2015
Endo pushes further into generics with $8 bln Par Pharma buy May 18 2015
5 Dividend Darlings Poised To Take Off: AstraZeneca plc, RSA Insurance Group plc, Cobham plc, N... May 18 2015
AstraZeneca to invest £182m to expand drug plant in Sweden May 18 2015
AstraZeneca to invest $285 million in Swedish biotech drug factory May 18 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK